$2.43
1.25% yesterday
Nasdaq, Jul 09, 10:00 pm CET
ISIN
US23666P1012
Symbol
DARE
Sector
Industry

Dare Bioscience, Inc. Stock price

$2.44
-0.69 21.92% 1M
-0.81 24.92% 6M
-0.68 21.79% YTD
-0.69 22.04% 1Y
-12.32 83.47% 3Y
-10.04 80.45% 5Y
-525.56 99.54% 10Y
-819.56 99.70% 20Y
Nasdaq, Closing price Wed, Jul 09 2025
+0.04 1.67%
ISIN
US23666P1012
Symbol
DARE
Sector
Industry

Key metrics

Basic
Market capitalization
$21.2m
Enterprise Value
$13.4m
Net debt
positive
Cash
$10.3m
Shares outstanding
8.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
236.0 | 2.2
EV/Sales
148.9 | 1.4
EV/FCF
2.2
P/B
negative
Financial Health
Equity Ratio
-27.2%
Return on Equity
67.4%
ROCE
63.5%
ROIC
-
Debt/Equity
-0.3
Financials (TTM | estimate)
Revenue
$90.0k | $9.8m
EBITDA
$-1.4m | -
EBIT
$-1.6m | $-25.4m
Net Income
$-1.7m | $-18.3m
Free Cash Flow
$6.0m
Growth (TTM | estimate)
Revenue
-96.8% | 97,600.0%
EBITDA
95.0% | -
EBIT
94.3% | -8.2%
Net Income
94.2% | -351.6%
Free Cash Flow
119.9%
Margin (TTM | estimate)
Gross
108.5%
EBITDA
-1,608.4% | -
EBIT
-1,820.1%
Net
-1,871.1% | -187.3%
Free Cash Flow
6,711.6%
More
EPS
$-0.2
FCF per Share
$0.7
Short interest
0.5%
Employees
22
Rev per Employee
$0.0
Show more

Is Dare Bioscience, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Dare Bioscience, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Dare Bioscience, Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Dare Bioscience, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Dare Bioscience, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.09 0.09
97% 97%
100%
- Direct Costs -0.01 -0.01
200% 200%
-11%
0.10 0.10
-
111%
- Selling and Administrative Expenses 8.87 8.87
23% 23%
9,856%
- Research and Development Expense 13 13
34% 34%
14,633%
-1.44 -1.44
95% 95%
-1,600%
- Depreciation and Amortization 0.19 0.19
375% 375%
211%
EBIT (Operating Income) EBIT -1.63 -1.63
94% 94%
-1,812%
Net Profit -1.68 -1.68
94% 94%
-1,867%

In millions USD.

Don't miss a Thing! We will send you all news about Dare Bioscience, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dare Bioscience, Inc. Stock News

Neutral
GlobeNewsWire
27 days ago
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company's 2025 annual meeting of stockholders (the “Annual Meeting”) was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is nec...
Neutral
Seeking Alpha
about 2 months ago
Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator Welcome to the Conference Call hosted by Daré Bioscience to review the company's First Quarter 2025 Fi...
Neutral
GlobeNewsWire
about 2 months ago
In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026 In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probioti...
More Dare Bioscience, Inc. News

Company Profile

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Sabrina Johnson
Employees 22
Founded 2015
Website www.darebioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today